menu
    • menu

    Company profile for Denali Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Denali was founded by scientists, drug developers and investors who share the vision that recent scientific insights in genetics, biology and translational medicine offer an unprecedented opportunity to discover and develop effective medicines for patients suffering from neurodegenerative disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Denali TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    151 Oyster Point Blvd - South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.denalitherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Denali Therapeutics, Royalty Pharma Ink $275M Royalty Deal
    Denali Therapeutics, Royalty Pharma Ink $275M Royalty Deal

    06 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3199643/0/en/Denali-Therapeutics-and-Royalty-Pharma-Announce-275-Million-Royalty-Funding-Agreement.html

    GLOBENEWSWIRE
    06 Dec 2025
    Share Share
    Denali Ph. 1 Pompe Plans Hit With Clinical Hold
    Denali Ph. 1 Pompe Plans Hit With Clinical Hold

    04 Dec 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/denali-phase-1-pompe-disease-trial-hit-clinical-hold

    FIERCE BIOTECH
    04 Dec 2025
    Share Share
    Denali Therapeutics Unveils Q3 2025 Financials & Business
    Denali Therapeutics Unveils Q3 2025 Financials & Business

    06 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/06/3183053/0/en/Denali-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html

    GLOBENEWSWIRE
    06 Nov 2025
    Share Share
    Denali Pharma Reveals Leadership Changes
    Denali Pharma Reveals Leadership Changes

    06 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/06/3183032/0/en/Denali-Therapeutics-Announces-Board-and-Executive-Leadership-Updates.html

    GLOBENEWSWIRE
    06 Nov 2025
    Share Share
    Denali's Hunter Syndrome Drug Latest To Be Hit By FDA Delay
    Denali's Hunter Syndrome Drug Latest To Be Hit By FDA Delay

    14 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/denalis-hunter-syndrome-drug-latest-be-hit-fda-decision-delay

    FIERCE BIOTECH
    14 Oct 2025
    Share Share
    Denali Extends FDA Review Of Tividenofusp Alfa For MPS II
    Denali Extends FDA Review Of Tividenofusp Alfa For MPS II

    13 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/13/3165786/0/en/Denali-Therapeutics-Announces-FDA-Review-Extension-of-BLA-for-Tividenofusp-Alfa-for-the-Treatment-of-MPS-II-Hunter-Syndrome.html

    GLOBENEWSWIRE
    13 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search